Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
SlideShare a Scribd company logo

merck 4Q08 Other Financial Disclosures

•
•
F
finance11

- Merck reported financial results for the fourth quarter and full year of 2008, including equity income from joint ventures and sales details. - For the fourth quarter, equity income from affiliates was $720 million, down 9% from the previous year. Sales from key joint ventures like Merial and Sanofi Pasteur-MSD also declined. - For the full year, total pharmaceutical sales were $23.85 billion, down 1%. U.S. sales fell 9% due to lower prices and volumes, while foreign sales rose 10% due to higher volumes partially offset by lower prices and exchange rates.

1 of 3
MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2008 EQUITY INCOME FROM AFFILIATES (millions of dollars) 4Q `08 4Q `07 YTD 2008 YTD 2007 MERCK / SCHERING-PLOUGH $ 378.1 $ 537.7 $ 1,536.3 $ 1,830.8 ASTRAZENECA LP 266.8 211.8 598.4 820.1 Other (1) 75.1 46.8 425.9 325.6 TOTAL $ 720.0 $ 796.3 $ 2,560.6 $ 2,976.5 (1) Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals. JOINT VENTURE SALES DETAIL (millions of dollars) All sales reported here are end-market JV sales, presented on a quot;NETquot; basis. Merial 4Q `08 4Q `07 YTD 2008 YTD 2007 $ 152.0 $ 167.2 $ 1,053.0 $ 1,033.3 FRONTLINE, other fipronil 208.8 202.1 789.7 674.9 BIOLOGICALS IVOMEC, HEARTGARD, other avermectins 96.8 111.7 511.8 478.4 67.4 70.2 288.2 262.2 Other Animal Health $ 525.0 $ 551.2 $ 2,642.7 $ 2,448.8 TOTAL MERIAL SALES Sanofi Pasteur-MSD 4Q `08 4Q `07 YTD 2008 YTD 2007 GARDASIL $ 171.2 $ 231.0 $ 865.3 $ 476.0 VIRAL VACCINES 24.4 21.8 105.1 86.8 HEPATITIS VACCINES 15.9 19.0 72.6 72.9 Other Vaccines 265.1 267.3 841.8 802.3 TOTAL SANOFI PASTEUR-MSD SALES $ 476.6 $ 539.1 $ 1,884.8 $ 1,438.0 Merck / Schering-Plough Collaboration 4Q `08 4Q `07 YTD 2008 YTD 2007 VYTORIN $ 549.5 $ 775.9 $ 2,360.0 $ 2,779.1 ZETIA 524.7 678.6 2,201.1 2,407.1 TOTAL MERCK / SCHERING-PLOUGH SALES $ 1,074.2 $ 1,454.5 $ 4,561.1 $ 5,186.2 OTHER (INCOME) EXPENSE, NET (millions of dollars) 4Q `08 4Q `07 YTD 2008 YTD 2007 INTEREST INCOME $ (147.2) $ (200.2) $ (631.4) $ (741.1) INTEREST EXPENSE 56.7 87.1 251.3 384.3 EXCHANGE LOSSES (GAINS) 73.8 (14.5) 147.4 (54.3) MINORITY INTERESTS 30.0 29.4 123.9 121.4 Other, net (1) (10.1) 665.6 (2,085.4) 335.9 TOTAL $ 3.2 $ 567.4 $ (2,194.2) $ 46.2 (1) Other, net for full year 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP. Other, net for the fourth quarter and full year 2007 reflects a civil governmental investigations charge of $671.1 million.
MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2008 NET PRODUCT SALES DETAIL (millions of dollars) 4Q `08 vs. 4Q `07 TOTAL TOTAL U.S. U.S. Foreign Foreign PRODUCT % CHG $ % CHG $ % CHG $ COZAAR / HYZAAR -1% 881 -3% 319 - 562 FOSAMAX -60% 318 -85% 77 -12% 241 SINGULAIR -3% 1,122 -11% 709 15% 413 Vaccines: GARDASIL -16% 286 -19% 216 -2% 69 ROTATEQ 9% 162 4 148 * 14 ZOSTAVAX 89% 162 89% 162 N/A - (1) OTHER VIRAL VACCINES -10% 295 -11% 278 3% 17 (2) HEPATITIS VACCINES -33% 40 -32% 33 -38% 7 OTHER VACCINES (3) 5% 132 8% 97 -2% 35 Other Reported Products: ARCOXIA -1% 83 N/A - -1% 83 CANCIDAS 4% 139 4% 21 4% 118 COSOPT / TRUSOPT -27% 154 -62% 37 1% 117 CRIXIVAN / STOCRIN -35% 52 -34% 3 -35% 49 EMEND 16% 71 23% 47 6% 24 INVANZ 29% 68 35% 38 21% 30 ISENTRESS * 130 * 71 * 59 JANUVIA 64% 413 41% 323 * 89 JANUMET * 120 * 99 * 20 MAXALT 12% 141 15% 97 7% 44 PRIMAXIN -13% 169 -24% 39 -10% 130 PROPECIA -4% 108 -5% 37 -3% 71 PROSCAR -14% 72 -46% 2 -12% 69 TIMOPTIC / TIMOPTIC XE -3% 31 -9% 2 -3% 29 VASOTEC / VASERETIC -32% 85 N/A - -32% 85 ZOCOR -34% 147 -80% 11 -19% 136 ZOLINZA 64% 5 62% 4 * - * 100% or over N/A - Not Applicable (1) - Includes ProQuad, M-M-R II and Varivax. (2) - Includes Recombivax and Vaqta (3) - Includes Pneumovax, Comvax and Pedvaxhib TOTAL SALES: VOLUME, PRICE, EXCHANGE 4Q '08 % CHG VOL PX FX TOTAL PHARMACEUTICAL SALES $ 6,032 -3% -4 1 -1 U.S. ($ MM) 3,396 -9% -12 4 N/A Foreign ($ MM) 2,636 5% 10 -3 -2
MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES DECEMBER YEAR-TO-DATE 2008 NET PRODUCT SALES DETAIL (millions of dollars) DECEMBER YTD `08 vs. DECEMBER YTD `07 TOTAL TOTAL U.S. U.S. Foreign Foreign PRODUCT % CHG $ % CHG $ % CHG $ COZAAR / HYZAAR 6% 3,558 1% 1,247 9% 2,311 FOSAMAX -49% 1,553 -75% 498 -1% 1,054 SINGULAIR 2% 4,337 -6% 2,825 19% 1,511 Vaccines: GARDASIL -5% 1,403 -13% 1,041 26% 362 ROTATEQ 27% 665 24% 618 83% 46 ZOSTAVAX 32% 312 32% 312 N/A - (1) OTHER VIRAL VACCINES -6% 1,268 -8% 1,175 38% 94 (2) HEPATITIS VACCINES -47% 148 -52% 112 -21% 36 OTHER VACCINES (3) -13% 355 -32% 206 38% 149 Other Reported Products: ARCOXIA 15% 377 N/A - 15% 377 CANCIDAS 11% 596 -21% 100 21% 496 COSOPT / TRUSOPT -1% 781 -17% 291 12% 491 CRIXIVAN / STOCRIN -11% 275 -36% 13 -10% 262 EMEND 29% 264 24% 172 41% 92 INVANZ 39% 265 32% 138 48% 127 ISENTRESS * 361 * 202 * 159 JANUVIA * 1,397 79% 1,110 * 287 JANUMET * 351 * 308 * 43 MAXALT 13% 529 13% 354 14% 175 PRIMAXIN - 760 -22% 163 8% 598 PROPECIA 6% 429 -1% 151 10% 278 PROSCAR -21% 324 -79% 12 -12% 311 TIMOPTIC / TIMOPTIC XE 2% 122 -10% 7 2% 115 VASOTEC / VASERETIC -28% 357 N/A - -28% 357 ZOCOR -25% 660 -59% 75 -16% 585 ZOLINZA 40% 15 34% 14 * 1 * 100% or over N/A - Not Applicable (1) - Includes ProQuad, M-M-R II and Varivax. (2) - Includes Recombivax and Vaqta (3) - Includes Pneumovax, Comvax and Pedvaxhib TOTAL SALES: VOLUME, PRICE, EXCHANGE FY '08 % CHG VOL PX FX -- TOTAL PHARMACEUTICAL SALES $ 23,850 -1% -4 3 U.S. ($ MM) 13,370 -9% -11 2 N/A Foreign ($ MM) 10,480 10% 7 -4 7

More Related Content

merck 4Q08 Other Financial Disclosures

  • 1. MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2008 EQUITY INCOME FROM AFFILIATES (millions of dollars) 4Q `08 4Q `07 YTD 2008 YTD 2007 MERCK / SCHERING-PLOUGH $ 378.1 $ 537.7 $ 1,536.3 $ 1,830.8 ASTRAZENECA LP 266.8 211.8 598.4 820.1 Other (1) 75.1 46.8 425.9 325.6 TOTAL $ 720.0 $ 796.3 $ 2,560.6 $ 2,976.5 (1) Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals. JOINT VENTURE SALES DETAIL (millions of dollars) All sales reported here are end-market JV sales, presented on a quot;NETquot; basis. Merial 4Q `08 4Q `07 YTD 2008 YTD 2007 $ 152.0 $ 167.2 $ 1,053.0 $ 1,033.3 FRONTLINE, other fipronil 208.8 202.1 789.7 674.9 BIOLOGICALS IVOMEC, HEARTGARD, other avermectins 96.8 111.7 511.8 478.4 67.4 70.2 288.2 262.2 Other Animal Health $ 525.0 $ 551.2 $ 2,642.7 $ 2,448.8 TOTAL MERIAL SALES Sanofi Pasteur-MSD 4Q `08 4Q `07 YTD 2008 YTD 2007 GARDASIL $ 171.2 $ 231.0 $ 865.3 $ 476.0 VIRAL VACCINES 24.4 21.8 105.1 86.8 HEPATITIS VACCINES 15.9 19.0 72.6 72.9 Other Vaccines 265.1 267.3 841.8 802.3 TOTAL SANOFI PASTEUR-MSD SALES $ 476.6 $ 539.1 $ 1,884.8 $ 1,438.0 Merck / Schering-Plough Collaboration 4Q `08 4Q `07 YTD 2008 YTD 2007 VYTORIN $ 549.5 $ 775.9 $ 2,360.0 $ 2,779.1 ZETIA 524.7 678.6 2,201.1 2,407.1 TOTAL MERCK / SCHERING-PLOUGH SALES $ 1,074.2 $ 1,454.5 $ 4,561.1 $ 5,186.2 OTHER (INCOME) EXPENSE, NET (millions of dollars) 4Q `08 4Q `07 YTD 2008 YTD 2007 INTEREST INCOME $ (147.2) $ (200.2) $ (631.4) $ (741.1) INTEREST EXPENSE 56.7 87.1 251.3 384.3 EXCHANGE LOSSES (GAINS) 73.8 (14.5) 147.4 (54.3) MINORITY INTERESTS 30.0 29.4 123.9 121.4 Other, net (1) (10.1) 665.6 (2,085.4) 335.9 TOTAL $ 3.2 $ 567.4 $ (2,194.2) $ 46.2 (1) Other, net for full year 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP. Other, net for the fourth quarter and full year 2007 reflects a civil governmental investigations charge of $671.1 million.
  • 2. MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2008 NET PRODUCT SALES DETAIL (millions of dollars) 4Q `08 vs. 4Q `07 TOTAL TOTAL U.S. U.S. Foreign Foreign PRODUCT % CHG $ % CHG $ % CHG $ COZAAR / HYZAAR -1% 881 -3% 319 - 562 FOSAMAX -60% 318 -85% 77 -12% 241 SINGULAIR -3% 1,122 -11% 709 15% 413 Vaccines: GARDASIL -16% 286 -19% 216 -2% 69 ROTATEQ 9% 162 4 148 * 14 ZOSTAVAX 89% 162 89% 162 N/A - (1) OTHER VIRAL VACCINES -10% 295 -11% 278 3% 17 (2) HEPATITIS VACCINES -33% 40 -32% 33 -38% 7 OTHER VACCINES (3) 5% 132 8% 97 -2% 35 Other Reported Products: ARCOXIA -1% 83 N/A - -1% 83 CANCIDAS 4% 139 4% 21 4% 118 COSOPT / TRUSOPT -27% 154 -62% 37 1% 117 CRIXIVAN / STOCRIN -35% 52 -34% 3 -35% 49 EMEND 16% 71 23% 47 6% 24 INVANZ 29% 68 35% 38 21% 30 ISENTRESS * 130 * 71 * 59 JANUVIA 64% 413 41% 323 * 89 JANUMET * 120 * 99 * 20 MAXALT 12% 141 15% 97 7% 44 PRIMAXIN -13% 169 -24% 39 -10% 130 PROPECIA -4% 108 -5% 37 -3% 71 PROSCAR -14% 72 -46% 2 -12% 69 TIMOPTIC / TIMOPTIC XE -3% 31 -9% 2 -3% 29 VASOTEC / VASERETIC -32% 85 N/A - -32% 85 ZOCOR -34% 147 -80% 11 -19% 136 ZOLINZA 64% 5 62% 4 * - * 100% or over N/A - Not Applicable (1) - Includes ProQuad, M-M-R II and Varivax. (2) - Includes Recombivax and Vaqta (3) - Includes Pneumovax, Comvax and Pedvaxhib TOTAL SALES: VOLUME, PRICE, EXCHANGE 4Q '08 % CHG VOL PX FX TOTAL PHARMACEUTICAL SALES $ 6,032 -3% -4 1 -1 U.S. ($ MM) 3,396 -9% -12 4 N/A Foreign ($ MM) 2,636 5% 10 -3 -2
  • 3. MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES DECEMBER YEAR-TO-DATE 2008 NET PRODUCT SALES DETAIL (millions of dollars) DECEMBER YTD `08 vs. DECEMBER YTD `07 TOTAL TOTAL U.S. U.S. Foreign Foreign PRODUCT % CHG $ % CHG $ % CHG $ COZAAR / HYZAAR 6% 3,558 1% 1,247 9% 2,311 FOSAMAX -49% 1,553 -75% 498 -1% 1,054 SINGULAIR 2% 4,337 -6% 2,825 19% 1,511 Vaccines: GARDASIL -5% 1,403 -13% 1,041 26% 362 ROTATEQ 27% 665 24% 618 83% 46 ZOSTAVAX 32% 312 32% 312 N/A - (1) OTHER VIRAL VACCINES -6% 1,268 -8% 1,175 38% 94 (2) HEPATITIS VACCINES -47% 148 -52% 112 -21% 36 OTHER VACCINES (3) -13% 355 -32% 206 38% 149 Other Reported Products: ARCOXIA 15% 377 N/A - 15% 377 CANCIDAS 11% 596 -21% 100 21% 496 COSOPT / TRUSOPT -1% 781 -17% 291 12% 491 CRIXIVAN / STOCRIN -11% 275 -36% 13 -10% 262 EMEND 29% 264 24% 172 41% 92 INVANZ 39% 265 32% 138 48% 127 ISENTRESS * 361 * 202 * 159 JANUVIA * 1,397 79% 1,110 * 287 JANUMET * 351 * 308 * 43 MAXALT 13% 529 13% 354 14% 175 PRIMAXIN - 760 -22% 163 8% 598 PROPECIA 6% 429 -1% 151 10% 278 PROSCAR -21% 324 -79% 12 -12% 311 TIMOPTIC / TIMOPTIC XE 2% 122 -10% 7 2% 115 VASOTEC / VASERETIC -28% 357 N/A - -28% 357 ZOCOR -25% 660 -59% 75 -16% 585 ZOLINZA 40% 15 34% 14 * 1 * 100% or over N/A - Not Applicable (1) - Includes ProQuad, M-M-R II and Varivax. (2) - Includes Recombivax and Vaqta (3) - Includes Pneumovax, Comvax and Pedvaxhib TOTAL SALES: VOLUME, PRICE, EXCHANGE FY '08 % CHG VOL PX FX -- TOTAL PHARMACEUTICAL SALES $ 23,850 -1% -4 3 U.S. ($ MM) 13,370 -9% -11 2 N/A Foreign ($ MM) 10,480 10% 7 -4 7